Testing for the presence of Mycobacterium tuberculosis Beijing genotype strains in Syrian samples  by Rahmo, Abdulkader et al.
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 1 ( 2 0 1 2 ) 8 7 –9 3
.sc ienced i rec t .comAvai lab le a t wwwjournal homepage: www.elsevier .com/ locate / IJMYCOTesting for the presence of Mycobacterium tuberculosis Beijing
genotype strains in Syrian samplesAbdulkader Rahmo a,*, Buthainah Alsalamah a, Maya Habous b
a National Commission for Biotechnology, Damascus, Syria
b Reference Tuberculosis Laboratory, Ministry of Health, Damascus, SyriaA R T I C L E I N F O
Article history:
Received 27 May 2012
Accepted 27 May 2012
Available online 15 June 2012
Keywords:
Beijing strain
Mycobacterium tuberculosis
Real-time PCR
DNA melting
Syria2212-5531/$ - see front matter  2012 Asian
http://dx.doi.org/10.1016/j.ijmyco.2012.05.004
* Corresponding author.
E-mail address: a.rahmo@gmail.com (A. RA B S T R A C T
The Beijing family of Mycobacterium tuberculosis (MTB) has been reported to have an excep-
tional capacity to spread tuberculosis (TB) and induce multi-drug resistance. A method has
been developed to distinguish this family from the rest of the MTB families through real-
time DNA amplification and subsequent analysis of the melting point of an amplicon.
Two pools of multi-drug resistant (MDR) MTB samples collected at two different time peri-
ods from various regions in Syria have been selected. This preliminary screening indicated
a complete absence of the Beijing family in all samples. This research presents an effective
differentiation of bacterial Beijing strains, with minimal effort and cost through analysis of
differential amplicon melting points.
 2012 Asian-African Society for Mycobacteriology. All rights reserved.Introduction
Tuberculosis (TB) is one of the main infectious causes of
death worldwide, with more than 9 million new cases of ac-
tive disease every year and nearly 2 million deaths [1]. TB is
an endemic disease in Syria and accounts for thousands of
notified cases (new and relapse incidence rate: 21/100,000
pop/year) [2]. Mycobacterium tuberculosis (MTB) is the causa-
tive agent of most TB cases; its ability to spread and the out-
come of infection depend on epidemiological, host and
bacterial factors [1]. Cases of drug resistant (DR) and multi-
drug resistant (MDR) TB (i.e., at least resistant to rifampicin
[RIF] and isoniazid [INH]) are increasing worldwide. In some
parts of the world 10% or more of new TB cases are MDR [3].
In the Baltic region and Russia a large increase in DR–TB has
occurred during the last two decades [4]. During this period
many Russians of Jewish descent immigrated to the Middle
East (Palestine).-African Society for Myco
ahmo).Strains with changed biological properties belonging to the
Beijing family of strains have been implicated in many out-
breaks of TB suggesting a more efficient transmission or an
enhanced ability to progress to active disease compared with
other TB strains [5]. Beijing strains, in vitro and in vivomodels,
show more virulent phenotypes than other MTB lineages.
They are often associated strongly with primary drug resis-
tance, and cause in some regions clusters ten times as big
as ‘‘traditional’’ strains [6]. Beijing strains appear better
adapted to intracellular growth, and drug resistance. They
have specific properties in terms of protein and lipid struc-
tures, which allow the immune-modulation of the host re-
sponse to the pathogen [7].
Beijing strains represent about 50% of the strains in East
Asia and at least 13% of the strains worldwide [8]. They
appear to spread further and establish themselves in new re-
gions. In Cape Town during the period 2000–2003, the Beijing
clade spread and became the cause of disease in children; thebacteriology. All rights reserved.
Table 1 – The sex, source and resistance pattern (Rif:
rifampicin; INH: isoniazid; Strp: streptomycin; EMB: eth-
ambutol) of sample pools, collected between 2010–2011 and
2003–2005.
Sample Sex Address Rif/INH/Strp/EMB
1 Male Aleppo RRRR
2 Male Aleppo RRSS
3 Male
4 Female Aleppo RRRR
5 Male Damascus RRRR
6 Male RifDamas RRRS
7 Male Rakka RRRS
8 Male DerAzour RRRR
9 Male DerAzour RRRS
10 Male Aleppo RRSS
11 Male Hama RRRS
12 Male Aleppo RRRR
13 Female Aleppo RRSS
14 Male Aleppo RRRR
15 Male Aleppo RRSS
16 Male Aleppo RRRR
17 Male DerAzour RRRR
18 Male DerAzour RRRR
19 Male Aleppo RRRR
20 Male Aleppo RRRR
21 Male Kamishly RRRR
22 Male Aleppo RRRR
23 Female Latakia RRRR
24 Female Aleppo RRRR
25 Male DerAzour RRRR
26 Female Damascus RRRR
27 Female Aleppo RRRR
28 Male Aleppo RRRR
29 Female Aleppo RRRR
30 Female Aleppo RRRR
31 Female Iraq RRRR
32 Male DerAzour RRRR
33 Male Iraq RRRR
34 Male Damascus RRRR
35 Female Aleppo RRRR
36 Male Hasaka RRRR
37 Male DerAzour RRRR
38 Male Aleppo RRRR
39 Female Aleppo RRRR
40 Female Aleppo RRRR
41 Male RifDamas RRRR
42 Male Hama RRRR
43 Female Damascus RRRR
44 Male Qunaitra RRRR
45 Male Kamishly RRRR
46 Male Damascus RRRR
47 Male Damascus RRRR
48 Male Aleppo RRRR
49 Male Damascus RRRR
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of 13% [9]. It has been suggested that the emergence of the
Beijing genotype family represents an evolutionary response
of MTB to THE BCG vaccination or/and antibiotic treatment,
resulting in a significant impact on TB control [10].
Active disease caused by Beijing strains was associated, in
some populations, with exceptional clinical phenotypes. In a
study in Russia, Beijing strains were associated with more se-
vere radiographic manifestations of pulmonary TB. Other
studies associated the Beijing family with extra-pulmonary
TB, a more likely poor outcome in elderly patients, and in
many areas an increased risk for relapse [5].
Recent studies have shown associations among MTB
strains, geographic regions, and human populations. These
indicate that specific strains of MTB coevolved with human
subpopulations [5]. The clinical presentations of patients with
tuberculosis caused by a Beijing strain were found to vary be-
tween different geographical settings [8]. Currently, the exact
origin of observed variability in a clinical presentation is still
unknown [8]. The prevalence of Beijing strains has not yet
been studied in Syria despite the reported presence of these
strains in neighboring countries and the influx of workers
from the Far East.
The real-time polymerase chain reaction (PCR) method
used by the authors is an earlier modification of the assay
presented by Hillemann et al. [11]; it targets the same TB gen-
ome loci, but detection was based on SYBR Green amplicon
detection, followed by profiling of the characteristic melting
point of the amplicon. This research applies a quantitatively
efficient, qualitatively unequivocal and sensitive assay for
the detection of a virulent Beijing strain. Samples collected
were from two different periods and from a pool of MDR
MTB. The research was entirely performed at the National
Commission for Biotechnology in Damascus, Syria.
Materials and methods
MTB samples
The first pool (22 samples) was collected between 2003 and
2005. The second pool (29 samples) was collected between
2010 and 2011 from various regions in Syria (Table 1). All sam-
ples represent MDR MTB. Drug resistance was established fol-
lowing the guidelines by the National Committee for Clinical
Laboratory Standards (NCCLS) [12]. Control DNA of Beijing
and non-Beijing strains were obtained from Azm Center for
Biotechnology at the Lebanese university [13]. Association
with the Beijing family strains had been established earlier
through the standard method of spoligotyping. The research
has been approved by the institutional bioethical committee.
DNA extraction
DNA extraction was applied with maximum precautions un-
der a biosafety class II hood [13]. Isolates (about 10 mg of col-
onies) are incubated in a water bath at 80 C for about 30 min
to kill the bacteria and centrifuged for 10 min at 8000 rpm. TE
buffer containing 1% Triton X-100, 0.5% Tween 20, 10 mM Tris–
HCl pH 8.0 and 1 mM EDTAwas added to the pellet. The rest ofthe procedure was according to instructions provided by Qia-
gen DNA Blood Mini Kit (Qiagen Germany), with the following
minor modification: the period of incubation at 37 C was for
2 h instead of 90 min.
Real-time PCR assay
Real-time PCR experiments were run using the Stratagene
Mx3005. Primerswere synthesized according to the sequence
Fig. 1 – The melting temperature profile for non-Beijing/Beijing samples using the specific designated primers.
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VBC Biotech (HPLC grade). PCR polymerase mix – DyNAmo
flash SYBR Green qPCR kit – was purchased from Finnzymes.
The primer concentrations used were 0.5 lM. Final reaction
volume was 50 ll, and MTB genome DNA amount added was
5 ll after 1000· dilution. The thermal profile was: 95 for
10 min, and 40–50 two steps cycle; consisting of a denaturation
step: 92 C for 15 s, and an annealing/extension step: 62 C for
one min. Measuring the derivative of fluorescence emission
with respect to temperature and plotting it against tempera-
ture unveiled the presence of a peak reflecting the melting
temperature of the amplicon that is diagnostic of the Beijing
family (Tm: 87.23 C, SE: 0.01), and one that is specific to the
non-Beijing family strains (Tm: 82.67 C, SE: 0.11) [14].Amplicon melting point temperature
Determination of the dissociation curve, and the melting
point temperature (Tm), which is based on maximal fluores-
cence emission change at varying temperatures multiplied
by 1; (dF/dT) was performed at the temperature range
[60–94 C], using the Fam filter (kex: 492 nm, kem: 516 nm) suit-
able for the SYBR Green flourophore. The applied software
was: MxPro from Stratagene.
Statistical calculations
Standard error (SE) was calculated using Microsoft Office Ex-
cel software.
Table 2 – The melting point analysis (Tm: melting point, Emi: emission) of amplified MTB DNA, using Beijing strain specific
primers (B) and non-Beijing strain specific primers (nB).
Sample 2010/2011 Primer Tm1 Emi Tm2 Emi Tm3 Emi Tm4 Emi Tm5 Emi Tm6 Emi
1 B 78.5 1445.78 89.18 3634 91.88 2039.56
2 B 77.95 1948.22 85.45 1382.11 89.72 1948.22
3 B 77.97 2277.78 85.97 1255 89.72 1069
4 B 77.97 940.33 91.3 2564.78
5 B 78.45 1494.44 91.28 4228.67
6 B 78.45 1850.33 85.85 1816.83 89.58 1465.67
7 B 78.4 833.67 88.72 5012
8 B 78.35 3984
9 B 78 2140.5 85.85 1208.5 86.67 1162 89.15 877.17
10 B 78.4 1180.33 88.75 4409.67
11 B 78.03 759 89.1 4945.5
12 B 78.35 3625
13 B 77.95 3176 85 686.5
14 B 77.58 809.17 85.85 846.17 88.78 4513.17
15 B 78.4 3059.67 85.85 586.5 89.15 679.17
16 B 78 1780.33 85.85 1305.5 90.35 1606.67
17 B 77.95 2361.17 85.4 1165.5
18 B 77.5 1875.17 85.78 1109.5
19 B 78 1484.83 88.75 3014.5
20 B 78 884 85.4 919.83 88.72 5201.5
21 B 77.95 4195 85.83 421.83
22 B 78.4 884.33 85.03 1002.83 88.72 5121.5
B C B 77.72 1048.33 87.18 2377.67
nB C B 77.85 1132.17 85.2 644.17 88.9 4356.5
1 nB 83.22 3756.22
2 nB 83.18 4458
3 nB 83.17 4166.22
4 nB 83.15 5930.11
5 nB 82.9 5876.83
6 nB 82.85 7918.5
7 nB 82.85 6773.5
8 nB 82.45 6663.83
9 nB 82.95 5775.17
10 nB 82.53 4826
11 nB 82.47 5178.67
12 nB 82.45 4479.5
13 nB 82.5 5550.83
14 nB 82.95 4551.17
15 nB 82.58 5030.5
16 nB 82.47 6523.17
17 nB 82.45 4853.83
18 nB 82.5 4982.67
19 nB 82.58 4980.17
20 nB 82.47 5340.83
21 nB 82.45 7164.67
22 nB 82.47 6450.33
B C nB 77.45 4765
nB C nB 81.85 2508.33
23 B 78.35 1016.83 85.38 669.5 89.05 3364.17
24 B 78.30 2264.33 85.7 846 89.85 479
25 B 77.85 1934.83 85.7 444.17 89.45 240.17
26 B 78.28 1289.83 88.58 1230.83 91.45 2603.5
27 B 77.4 726 88.95 1536.17
28 B 77.45 859 85.78 766.33 90.3 833.83
29 B 78.3 967.17 89.05 2121.33
30 B 77.45 900 85.7 870.33 89.85 939.17
31 B 77.85 764.83 91.45 1939.83
32 B 77.4 1245 85.28 641.17
33 B 89.4 2056.17
34 B 77.85 1160.17 88.5 2873.33
35 B 77.85 1357.83 85.6 708.83 88.9 499.67
36 B 77.35 1174.83 85.6 704.17 89.35 597
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Table 2 – (continued)
Sample 2010/2011 Primer Tm1 Emi Tm2 Emi Tm3 Emi Tm4 Emi Tm5 Emi Tm6 Emi
37 B 77.47 530.83 89 1382.67
38 B 77.85 881 89 3237.17
39 B 77.85 877.67 88.5 1455.33 90.97 910.5
40 B 88.55 2423.5
41 B 78.13 1063.78 89.03 1962 91.3 2142.89
42 B 78.28 2417.67 85.65 550
43 B 78.28 1199.33 89 4436.5
44 B 78.28 1666.17 85.6 1339.33 89.78 1743.5
45 B 77.85 1914.17 85.6 1129.33 89.35 898
46 B 78.28 2337.17 86.1 820.33
47 B 77.85 1630.83 85.65 699.67 89.4 1112 91.4 2905.17
48 B 78.65 1675.17 85.65 1197.67 89 1690.67
49 B 78.28 2189.17 85.6 1127.5 89.4 905.83
B C B 77.85 1132.17 85.2 644.17 88.9 4356.5
nB C B 77.78 1768.83 86.85 1621.67
23 nB 82.78 2885.89
24 nB 82.75 3628.22
25 nB 82.75 5295.56
26 nB 82.25 4399.33
27 nB 82.25 3104.11
28 nB 82.58 5588.83
29 nB 76.33 1336 82.53 3482.33
30 nB 82.53 5266.33
31 nB 81.7 2868.17
32 nB 82.1 3128.67
33 nB 82.95 2779
34 nB 82.58 2832.67
35 nB 82.47 4768.17
36 nB 82.47 3174.83
37 nB 82.58 4743.67
38 nB 82.53 3549
39 nB 75.9 533.33 81.65 1617
40 nB 82.47 2508.5
41 nB 82.78 5533
42 nB 82.83 2584.83
43 nB 82.83 3023.17
44 nB 82.78 2973.17
45 nB 82.35 2885.33
46 nB 82.78 1928.17
47 nB 82.78 4718
48 nB 82.83 3310
49 nB 82.78 3474.33
B C nB 81.85 2508.33
nB C nB 77.35 2406.67
B C: Beijing strain positive control; nB C: non-Beijing strain positive control; B: Beijing specific primer; nB: non-Beijing specific primer.
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Based on the analysis of BLASTN of the TB genome sequence,
the expected non-Beijing and Beijing family of strains ampli-
con length produced should be 129 bp for the Beijing strains,
and 95 bp for the non-Beijing strains [11].
Testing non-Beijing and Beijing primers on non-Beijing
and Beijing samples resulted in Tm peaks and associated
emissions as described in Fig. 1.
Testing non-Beijing primers on non-Beijing samples
resulted in one Tm peak (82.67 C, SE: 0.11). Using thenon-Beijing primers with a Beijing sample resulted in only
one Tm peak (77 C).
Testing Beijing primers on Beijing samples at 62 C anneal-
ing temperature resulted in two Tm peaks (78 C, 87.23 C).
Using Beijing primers on non-Beijing samples at 62 C anneal-
ing temperature resulted in several Tm peaks (78 C, 86 C,
90 C). The Tm peak at 87.23 C (SE: 0.01) is the diagnostic
peak used for the Beijing strains [14].
Exploring non-Beijing and Beijing strains on collected
samples resulted in Tm peaks and associated emissions as de-
scribed in Table 2.
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The results of the applied methodwere based on its clear abil-
ity to discriminate between the Beijing family strain and the
rest of the TB family strains. The distinction is based on the
amplified region near RV 2820 uniquely present in Beijing
strains, providing the specific fragment of 129 bp, and the
amplified region in Rv 2819 present solely in non-Beijing
strains; providing the specific fragment of 95 bp.
The difference in diagnostic melting temperature (Tm val-
ues) obtained for Beijing and non-Beijing families (87.23 C,
82.67 C resp.) is consistent with the specific amplicon size
of Beijing strains being 36% larger than that of non-Beijing
strains.
Beijing family strains have been implicated in fast trans-
mission, which emphasizes the importance of a fast, simple
and economic detection method. The use of rapid diagnostics
would reduce the time for implementation of appropriate
treatment.
The major advantages of this method are its rapidity, sim-
plicity and sensitivity. The strains are quantifiable. The mod-
ified method presented does not require any further specific
probes or modified primers. The detection is carried out, un-
like the method by Hillemann et al. [11], based on just SYBR
Green selective binding to double stranded DNA. The use of
amplicon melting analysis is an established technique in dif-
ferential detection of microorganisms [15].
The observed variations in melting point of amplified
DNA in the various strains tested suggest significant genet-
ic variations among strains. This is expected since non-Bei-
jing samples likely represent a heterogeneous family of
strains.
The prevalence of Beijing strains in the Middle East and its
association with drug resistance has been unfortunately scar-
cely studied with some exceptions. In Iran reports indicate
that the overall prevalence of the Beijing genotype is 3.2%,
of which 21.7% are MDR [16]. An extensive study in Saudi Ara-
bia revealed a prevalence value of 4.5% [17].
The testing of all multi-resistant samples obtained from a
recent pool and from an earlier one indicated the absence of
any Beijing strain in these samples. Such absence if further
confirmed through larger sampling pools is striking given
the proven presence of Beijing strains in neighboring coun-
tries (Turkey, Palestine, Saudi Arabia). On the other hand, it
is possible that the Syrian population is less prone to infec-
tion by the Beijing family of strains [18]. This has been earlier
hypothesized for other cases of limited spread of the Beijing
genotype [10,19,20].Conclusion and recommendation
Using the present method allows for a fast assessment of epi-
demiological distribution and dynamics of the Beijing family
of strains; this may be of exceptional value in regions where
their contribution to TB is still unknown. Simplifying and
economizing the detection of the Beijing family provides for
a fast and widespread real-time surveillance of their epidemi-
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